This pioneering research, published in PLOS Medicine, meticulously quantifies the potential financial fallout from scaled-back global donor support, estimating an additional $7.5 billion in household costs annually in the 79 LMICs studied. These elevated costs encompass direct medical expenses, ancillary non-medical charges such as transportation and nutrition, and often overlooked but critical indirect costs — chiefly income lost during prolonged illness and treatment. Alarmingly, the World Health Organization’s End TB Strategy defines “catastrophic costs” as those exceeding 20% of household income, and the study projects that an additional four million households could cross this devastating threshold.

USAID historically accounted for roughly one-fifth of all international TB funding, playing an indispensable role in catalyzing and sustaining TB prevention and treatment initiatives globally. The Global Fund to Fight AIDS, TB, and Malaria, still a leading benefactor, provides over 75% of international TB financing, a substantial portion of which originates from the United States. Together, these agencies have been credited with preventing approximately 75 million TB deaths worldwide.

Between 2023 and 2024, positive strides were observed globally, including a near 2% decline in TB infection rates and a 3% reduction in mortality. Yet, these gains now face jeopardy with diminishing donor contributions. Should the worst-case scenario arise—where all international TB funding abruptly halts—the economic burden borne by households could escalate near $80 billion, a staggering surge that threatens not only public health achievements but could plunge millions into poverty.

The study utilizes sophisticated linked epidemiological and economic simulation models, incorporating a range of scenarios reflecting varying degrees of donor withdrawal. These scenarios include maintaining 2024 funding levels, removing USAID support alone, and successive combinations of USAID and Global Fund funding reductions, culminating in the total cessation of external financial aid. The models reveal a striking 32% increase in household TB-related costs in the worst-case context compared to pre-2025 levels, disproportionately impacting the poorest 20% of the population.

Dr. Portnoy highlights the multifaceted nature of TB-related household expenses. Direct medical costs, though sometimes subsidized, still burden families through diagnostic fees, consultations, and medications. Non-medical costs, often less visible, significantly include logistics such as transportation and temporary accommodation during treatment. More devastating are indirect costs — particularly lost earnings — as TB frequently incapacitates patients for prolonged periods.

The economic consequences of these costs are severe and far-reaching. Families often resort to depleting their savings, incurring debt, or liquidating assets to cover expenses. Such financial strain reverberates beyond immediate medical realms, hindering children’s education, undermining food security, and entrenching long-term economic instability within vulnerable communities.

While the study acknowledges limitations stemming from assumptions about the costs faced by untreated or undiagnosed patients and future healthcare dynamics, it robustly conveys the dire economic consequences of reduced international aid. Prior research, including a BUSPH study, already forecasts catastrophic health outcomes from funding cuts, predicting an additional 9 million pediatric TB cases and 1.5 million child deaths linked to the withdrawal of US support alone.

Faced with the prospect of dwindling global financial backing, the study authors emphasize the imperative for LMICs to fortify domestic health financing mechanisms and enhance primary healthcare system integration for TB services. Innovative financial protection strategies—ranging from direct cash transfers to subsidized transportation and social protection schemes—must be scaled up to counterbalance the indirect economic shocks of TB illness and therapy.

Crucially, donor withdrawal strategies require careful calibration. Sudden funding terminations can destabilize national TB programs, potentially reversing hard-won public health progress. Instead, phased, coordinated transitions incorporating blended finance models—combining governmental funding, private sector involvement, and targeted donor assistance—offer a pragmatic pathway to sustain TB control efforts amidst shifting fiscal landscapes.

As the global health community approaches World TB Day on March 24, this study serves as a clarion call: restoring and reinforcing international support for TB programs is essential not only to safeguard public health but also to alleviate the profound financial hardships faced by millions of vulnerable families worldwide. Sustained donor investment, coupled with strategic domestic reforms and innovative financing, is critical to realizing the promise of the End TB Strategy and ending the tuberculosis epidemic.

Subject of Research: People

Article Title: The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling study

News Publication Date: 20-Feb-2026

Web References:

• PLOS Medicine article
• WHO End TB Strategy
• Global gains in Tuberculosis response (WHO)

References:
Portnoy A. et al., “The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling study,” PLOS Medicine, February 2026.

Keywords: Tuberculosis, Respiratory disorders, Infectious diseases, Public health, Epidemics, Medical economics, Health care industry, Health care costs, Drug costs, Economics

Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, continues to pose a serious health burden worldwide, with millions of new cases annually and significant mortality, especially in low- and middle-income countries. Despite substantial advancements in diagnostics, treatment, and vaccination, reaching the ambitious goals set by the World Health Organization’s End TB Strategy has proven elusive. The persistence of TB is exacerbated by socioeconomic disparities, healthcare access inequalities, and the emergence of drug-resistant strains that complicate treatment protocols. Within this context, the traditional siloed approaches by public health authorities and independent private providers have limited impact, revealing the need for synergistic intervention models.

Public–private partnerships represent a strategic innovation that leverages the strengths of both sectors. Governments often command authority, extensive reach, and the mandate to deliver equitable healthcare access. Private entities, inclusive of for-profit clinics, pharmaceutical companies, and non-governmental organizations, contribute agility, innovation, and resources that can complement and expand public health initiatives. However, the complexity of integrating these sectors requires meticulous coordination, aligning incentives, establishing accountability mechanisms, and fostering mutual trust. Dr. Singh’s treatise meticulously evaluates these dimensions, providing a granular assessment of how PPPs can be operationalized effectively within TB control frameworks.

One of the principal challenges to forming effective PPPs is reconciling divergent goals. Public agencies are predominantly focused on public health metrics and equitable service delivery, whereas private sector entities often operate under market-driven imperatives. This tension can result in fragmented care pathways, duplicated efforts, or mission drift. Singh iterates that successful partnerships mandate transparent agreements where roles, responsibilities, and outcomes are clearly delineated. Such clarity reduces bureaucratic inertia and promotes a cohesive response that maximizes resource allocation efficiency. This conceptual framework strengthens governance structures critical to combating TB in diverse healthcare ecosystems.

Technological innovation features prominently in the potential of PPPs to reshape TB care. Incorporation of digital health tools, such as mobile diagnostics, electronic patient registries, and telemedicine platforms, enables real-time surveillance and enhanced patient monitoring. Public entities can facilitate regulatory oversight and data standardization, while private partners supply cutting-edge solutions and expedite technology dissemination. Singh highlights case studies demonstrating how these technological synergies have improved early detection rates, treatment adherence, and reporting accuracy, thereby disrupting the transmission cycle of TB and improving overall health outcomes.

Financial considerations present both obstacles and incentives within public–private alliances. While public funding often suffers from budgetary restrictions and unpredictability, private sector investment introduces capital infusion that can accelerate program scale-up. However, issues of cost recovery, equity in service provision, and pricing transparency require sophisticated financial models embedded within PPP agreements. Singh advocates for innovative financing mechanisms, including outcome-based contracts and co-financing arrangements, to align economic interests with public health imperatives, enhancing sustainability and scalability of TB interventions.

The regulatory landscape also demands rigorous attention. Divergent standards and policies between the public and private healthcare providers can undermine partnership efficacy. Harmonizing these frameworks to ensure quality assurance, patient safety, and ethical compliance is paramount. Dr. Singh emphasizes the role of governmental agencies in establishing unified regulatory environments that foster seamless integration of services, reduce unauthorized practices, and bolster public confidence in the healthcare system’s capacity to manage TB effectively.

Human resource capacity building is another cornerstone identified in the discourse. The disparity in skill sets, training levels, and operational protocols across public and private providers creates barriers to consistency in TB care delivery. By fostering cross-sectoral training programs and joint operational protocols, PPPs can standardize competencies, promote knowledge exchange, and build a cadre of healthcare workers equipped to manage complex TB cases collaboratively. Such investment improves not only clinical outcomes but also facilitates patient retention and trust within mixed health service environments.

Surveillance systems integration is vital for monitoring disease trends and tailoring interventions. Traditional public health surveillance mechanisms often lag in data granularity and timeliness, while private sectors may lack incentives to report cases systematically. PPPs can bridge this divide by developing interoperable information systems that aggregate data across multiple sources. Singh outlines strategic frameworks for data sharing agreements that protect patient confidentiality yet promote transparency, enabling real-time analytics critical for forecasting outbreaks and evaluating program impact.

Accessibility remains a linchpin in ending TB. Many patients are lost to follow-up due to geographic, financial, or social barriers. Public–private partnerships enable the establishment of decentralized service networks, leveraging private clinics’ proximity and operational flexibility alongside public health programs’ subsidized care models. Singh’s research elucidates how such integrated delivery pathways have significantly reduced patient attrition and improved adherence through tailored support mechanisms, such as community health workers and patient incentives, that address local context-specific challenges.

Disease stigma and health education form an intangible yet formidable barrier. TB can be associated with social ostracism, hindering patients from seeking care or disclosing status. Effective PPPs invest in coordinated communication strategies that normalize TB screening and treatment, involving community leaders and using culturally sensitive messaging. Dr. Singh documents successes where joint campaigns have dramatically increased community engagement and destigmatized TB, thereby fostering an environment conducive to early diagnosis and sustained treatment adherence.

Drug-resistant TB strains pose a grave threat to control efforts. These cases require sophisticated diagnostics, extended therapy, and monitoring regimens that strain health systems, particularly in resource-constrained settings. Public–private collaborations enable pooling of expertise and resources to enhance laboratory capacity, procure second-line drugs, and implement effective pharmacovigilance. Singh’s analysis underscores the critical nature of these partnerships in mounting comprehensive responses to drug resistance, derived from shared knowledge, financial commitment, and operational coordination.

The COVID-19 pandemic has further complicated TB control, disrupting healthcare delivery and diverting resources. However, it also emphasized the indispensability of agile PPP models. Leveraging infrastructure and lessons learned from pandemic response, such as contact tracing technology and rapid diagnostics, PPPs can bolster TB control resilience. Singh’s paper advocates capitalizing on this momentum to integrate TB programs within broader health emergency preparedness frameworks, ensuring sustained gains post-pandemic.

Equity considerations permeate the discussion. Marginalized populations disproportionately bear the TB burden but often have the least access to quality care. PPPs offer pathways to tailor interventions to these vulnerable groups through targeted outreach and culturally competent services. Singh argues that rigorous monitoring of equity indicators within partnership programs is necessary to prevent perpetuation of disparities and to ensure universal health coverage objectives are met.

Looking forward, the sustainability of public–private collaborations hinges upon political will, community engagement, and continuous innovation. Adaptive governance structures that incorporate feedback loops and iterative improvement processes are essential to respond dynamically to shifting TB epidemiology and healthcare landscapes. Singh concludes that the success of PPPs in ending tuberculosis will be defined not only by initial implementation but by their capacity to evolve, scale, and maintain relevance amid ongoing challenges.

Ultimately, this detailed exploration by Dr. Singh affirms that while public–private partnerships are not a panacea, they represent one of the most potent instruments in the global campaign to eradicate tuberculosis. Harnessing their potential demands deliberate design, robust accountability, and persistent commitment from all stakeholders. As the world inches towards the aspirational goal of a TB-free future, such synergistic collaborations stand as a beacon of hope and a testament to the transformative power of collective action.

Subject of Research: Public–private partnerships in tuberculosis control; strategies to overcome challenges and harness opportunities for ending TB.

Article Title: Public–private partnership to end tuberculosis: challenges and opportunities.

Article References:
Singh, S. Public–private partnership to end tuberculosis: challenges and opportunities. Int J Equity Health 24, 195 (2025). https://doi.org/10.1186/s12939-025-02516-0

Image Credits: AI Generated